Skip to main content

Study Name: AURORA / AURORA 02

A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis

Principal Investigator: Keisha Gibson, MD, MPH
Sponsor: Aurinia Pharmaceuticals Inc.
Age Range: 18-75
Status: Ongoing – Enrollment CLOSED

Purpose: To learn whether the investigational drug Orelvo (voclosporin) will decrease the amount of protein lost in the urine (proteinuria). Orelvo will be compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus of the kidney (lupus nephritis [LN])

Study Procedures: Orelvo is an oral medication taken twice daily. There are a total of 16 study visits over the course of a year. Blood and urine samples will be collected at each study visit.

Participation: Participation in the study will last approximately 1 year. Following the 52-week treatment period, participants may be able to continue taking the study medication for an additional 2 years (AURORA 02 study).

For more information, please contact:

Brenda Meier, RN
Study Coordinator